Molecular biology as a tool for the treatment of cancer

被引:30
作者
de Castro Sant' Anna, Carla [1 ,2 ]
Ferreira Junior, Alberto Gomes [1 ]
Soares, Paulo [1 ]
Tuji, Fabricio [1 ]
Paschoal, Eric [1 ]
Chaves, Luiz Claudio [1 ]
Burbano, Rommel Rodriguez [1 ]
机构
[1] Ophir Loyola Hosp, Mol Biol Lab, Ave Governador Magalhaes Barata 992, BR-66063240 Belem, Para, Brazil
[2] Joao de Barros Barreto Univ Hosp, Belem, Para, Brazil
关键词
Biomarkers; Epigenetics; Molecular biology; Cancer; CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; FAMILIAL GASTRIC-CANCER; TYROSINE KINASE INHIBITORS; MGMT PROMOTER METHYLATION; E-CADHERIN MUTATIONS; BCR-ABL TRANSCRIPTS; GERMLINE MUTATIONS; HELICOBACTER-PYLORI; IMATINIB-RESISTANT;
D O I
10.1007/s10238-018-0518-1
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Cancer is a genetic disease characterized by uncontrolled cell growth and metastasis. Cancer can have a number of causes, such the activation of oncogenes, the inactivation of tumor-suppressing genes, mutagenesis provoked by external factors, and epigenetic modifications. The development of diagnostic tools and treatments using a molecular biological approach permits the use of sensitive, low-cost, noninvasive tests for cancer patients. Biomarkers can be used to provide rapid, personalized oncology, in particular the molecular diagnosis of chronic myeloid leukemia, and gastric, colon, and breast cancers. Molecular tests based on DNA methylation can also be used to direct treatments or evaluate the toxic effects of chemotherapy. The adequate diagnosis, prognosis, and prediction of the response of cancer patients to treatment are essential to ensure the most effective therapy, reduce the damaging effects of treatment, and direct the therapy to specific targets, and in this context, molecular biology has become increasingly important in oncology. In this brief review, we will demonstrate the fundamental importance of molecular biology for the treatment of three types of cancerchronic myeloid leukemia, hereditary diffuse gastric cancer, and astrocytomas (sporadic tumors of the central nervous system). In each of these three models, distinct biological mechanisms are involved in the transformation of the cells, but in all cases, molecular biology is fundamental to the development of personalized analyses for each patient and each type of neoplasia, and to guarantee the success of the treatment.
引用
收藏
页码:457 / 464
页数:8
相关论文
共 118 条
  • [91] Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells
    Rix, L. L. Remsing
    Rix, U.
    Colinge, J.
    Hantschel, O.
    Bennett, K. L.
    Stranzl, T.
    Mueller, A.
    Baumgartner, C.
    Valent, P.
    Augustin, M.
    Till, J. H.
    Superti-Furga, G.
    [J]. LEUKEMIA, 2009, 23 (03) : 477 - 485
  • [92] Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
    Ross, David M.
    Branford, Susan
    Seymour, John F.
    Schwarer, Anthony P.
    Arthur, Christopher
    Yeung, David T.
    Phuong Dang
    Goyne, Jarrad M.
    Slader, Cassandra
    Filshie, Robin J.
    Mills, Anthony K.
    Melo, Junia V.
    White, Deborah L.
    Grigg, Andrew P.
    Hughes, Timothy P.
    [J]. BLOOD, 2013, 122 (04) : 515 - 522
  • [93] Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
    Rousselot, Philippe
    Huguet, Francoise
    Rea, Delphine
    Legros, Laurence
    Cayuela, Jean Michel
    Maarek, Odile
    Blanchet, Odile
    Marit, Gerald
    Gluckman, Eliane
    Reiffers, Josy
    Gardembas, Martine
    Mahon, Francois-Xavier
    [J]. BLOOD, 2007, 109 (01) : 58 - 60
  • [94] Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
    Rousselot, Philippe
    Charbonnier, Aude
    Cony-Makhoul, Pascale
    Agape, Philippe
    Nicolini, Franck E.
    Varet, Bruno
    Gardembas, Martine
    Etienne, Gabriel
    Rea, Delphine
    Roy, Lydia
    Escoffre-Barbe, Martine
    Guerci-Bresler, Agnes
    Tulliez, Michel
    Prost, Stephane
    Spentchian, Marc
    Cayuela, Jean Michel
    Reiffers, Josy
    Chomel, Jean Claude
    Turhan, Ali
    Guilhot, Joelle
    Guilhot, Francois
    Mahon, Francois-Xavier
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (05) : 424 - U59
  • [95] RETRACTED: Recurrent Glioblastoma: Where we stand(Retracted article. See vol. 6, pg. 153, 2017)
    Roy, Sanjoy
    Lahiri, Debarshi
    Maji, Tapas
    Biswas, Jaydip
    [J]. SOUTH ASIAN JOURNAL OF CANCER, 2015, 4 (04) : 163 - 173
  • [96] BCR-ABL1 mutation ≠ ponatinib resistance
    Saglio, Giuseppe
    Fava, Carmen
    [J]. BLOOD, 2016, 127 (06) : 666 - +
  • [97] Epigenetic regulation of DNA repair machinery in Helicobacter pylori-induced gastric carcinogenesis
    Santos, Juliana Carvalho
    Ribeiro, Marcelo Lima
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (30) : 9021 - 9037
  • [98] A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia
    Seymour, J. F.
    Kim, D. W.
    Rubin, E.
    Haregewoin, A.
    Clark, J.
    Watson, P.
    Hughes, T.
    Dufva, I.
    Jimenez, J. L.
    Mahon, F-X
    Rousselot, P.
    Cortes, J.
    Martinelli, G.
    Papayannidis, Cristina
    Nagler, A.
    Giles, F. J.
    [J]. BLOOD CANCER JOURNAL, 2014, 4 : e238 - e238
  • [99] Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia
    Shah, Neil P.
    Kantarjian, Hagop M.
    Kim, Dong-Wook
    Rea, Delphine
    Dorlhiac-Llacer, Pedro E.
    Milone, Jorge H.
    Vela-Ojeda, Jorge
    Silver, Richard T.
    Khoury, H. Jean
    Charbonnier, Aude
    Khoroshko, Nina
    Paquette, Ronald L.
    Deininger, Michael
    Collins, Robert H.
    Otero, Irma
    Hughes, Timothy
    Bleickardt, Eric
    Strauss, Lewis
    Francis, Stephen
    Hochhaus, Andreas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (19) : 3204 - 3212
  • [100] Familial gastric cancer:: clinicopathological characteristics, RER phenotype and germline p53 and E-cadherin mutations
    Shinmura, K
    Kohno, T
    Takahashi, M
    Sasaki, A
    Ochiai, A
    Guilford, P
    Hunter, A
    Reeve, AE
    Sugimura, H
    Yamaguchi, N
    Yokota, J
    [J]. CARCINOGENESIS, 1999, 20 (06) : 1127 - 1131